Novocure to Report First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Equities turn higher as Treasury yields drop from highs
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
NovoCure Ltd. (NVCR) PT Lowered to $42 at Wells Fargo
April 3, 2024 5:14 AM EDTWells Fargo analyst Larry Biegelsen lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $42.00 (from $49.00) while maintaining a Overweight rating.
The analyst comments "Sizing up the brain METS market. NVCR estimates ~17K patients a year that could be... More
